177 related articles for article (PubMed ID: 25584911)
1. The thrombogenicity of C1 esterase inhibitor (human): review of the evidence.
Crowther M; Bauer KA; Kaplan AP
Allergy Asthma Proc; 2014; 35(6):444-53. PubMed ID: 25584911
[TBL] [Abstract][Full Text] [Related]
2. Safety of C1-esterase inhibitor in acute and prophylactic therapy of hereditary angioedema: findings from the ongoing international Berinert patient registry.
Busse P; Bygum A; Edelman J; Lumry W; Machnig T; Martinez-Saguer I; Rojavin M
J Allergy Clin Immunol Pract; 2015; 3(2):213-9. PubMed ID: 25609333
[TBL] [Abstract][Full Text] [Related]
3. Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert
Bouillet L; Boccon-Gibod I; Gompel A; Floccard B; Martin L; Blanchard-Delaunay C; Launay D; Fain O
Eur J Dermatol; 2017 Apr; 27(2):155-159. PubMed ID: 28251901
[TBL] [Abstract][Full Text] [Related]
4. Assessment of hereditary angioedema treatment risks.
Kalaria S; Craig T
Allergy Asthma Proc; 2013; 34(6):519-22. PubMed ID: 24169059
[TBL] [Abstract][Full Text] [Related]
5. Treatment response after repeated administration of C1 esterase inhibitor for successive acute hereditary angioedema attacks.
Craig TJ; Bewtra AK; Hurewitz D; Levy R; Janss G; Jacobson KW; Packer F; Bernstein JA; Rojavin MA; Machnig T; Keinecke HO; Wasserman RL
Allergy Asthma Proc; 2012; 33(4):354-61. PubMed ID: 22856636
[TBL] [Abstract][Full Text] [Related]
6. Preprocedural administration of nanofiltered C1 esterase inhibitor to prevent hereditary angioedema attacks.
Grant JA; White MV; Li HH; Fitts D; Kalfus IN; Uknis ME; Lumry WR
Allergy Asthma Proc; 2012; 33(4):348-53. PubMed ID: 22856635
[TBL] [Abstract][Full Text] [Related]
7. Subcutaneous C1-esterase inhibitor to prevent hereditary angioedema attacks: Safety findings from the COMPACT trial.
Li HH; Mycroft S; Christiansen S; Wood DN; Feuersenger H; Pawaskar D; Jacobs I
Allergy Asthma Proc; 2018 Sep; 39(5):365-370. PubMed ID: 30107868
[TBL] [Abstract][Full Text] [Related]
8. Nanofiltered C1 esterase inhibitor for treatment of laryngeal attacks in patients with hereditary angioedema.
Riedl MA; Lumry WR; Li HH; Craig TJ; Fitts D; Kalfus I; Uknis ME
Am J Rhinol Allergy; 2013; 27(6):517-21. PubMed ID: 24274230
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study.
Moldovan D; Reshef A; Fabiani J; Kivity S; Toubi E; Shlesinger M; Triggiani M; Montinaro V; Cillari E; Realdi G; Cancian M; Visscher S; Zanichelli A; Relan A; Cicardi M
Clin Exp Allergy; 2012 Jun; 42(6):929-35. PubMed ID: 22909164
[TBL] [Abstract][Full Text] [Related]
10. Nanofiltered C1 esterase inhibitor (human) for the treatment of acute attacks of hereditary angioedema: an open-label trial.
Riedl MA; Hurewitz DS; Levy R; Busse PJ; Fitts D; Kalfus I
Ann Allergy Asthma Immunol; 2012 Jan; 108(1):49-53. PubMed ID: 22192966
[TBL] [Abstract][Full Text] [Related]
11. Risk of thromboembolism in patients with hereditary angioedema treated with plasma-derived C1-inhibitor.
Farkas H; Kőhalmi KV; Veszeli N; Zotter Z; Várnai K; Varga L
Allergy Asthma Proc; 2016; 37(2):164-70. PubMed ID: 26802388
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of C1 esterase inhibitor for acute attacks in children with hereditary angioedema.
Lumry W; Soteres D; Gower R; Jacobson KW; Li HH; Chen H; Schranz J
Pediatr Allergy Immunol; 2015 Nov; 26(7):674-80. PubMed ID: 26171584
[TBL] [Abstract][Full Text] [Related]
13. Current options for prophylactic treatment of hereditary angioedema in the United States: patient-based considerations.
Gower RG; Lumry WR; Davis-Lorton MA; Johnston DT; Busse PJ
Allergy Asthma Proc; 2012; 33(3):235-40. PubMed ID: 22584192
[TBL] [Abstract][Full Text] [Related]
14. C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks--final results of the I.M.P.A.C.T.2 study.
Craig TJ; Bewtra AK; Bahna SL; Hurewitz D; Schneider LC; Levy RJ; Moy JN; Offenberger J; Jacobson KW; Yang WH; Eidelman F; Janss G; Packer FR; Rojavin MA; Machnig T; Keinecke HO; Wasserman RL
Allergy; 2011 Dec; 66(12):1604-11. PubMed ID: 21884533
[TBL] [Abstract][Full Text] [Related]
15. Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate.
Zuraw BL; Cicardi M; Longhurst HJ; Bernstein JA; Li HH; Magerl M; Martinez-Saguer I; Rehman SM; Staubach P; Feuersenger H; Parasrampuria R; Sidhu J; Edelman J; Craig T
Allergy; 2015 Oct; 70(10):1319-28. PubMed ID: 26016741
[TBL] [Abstract][Full Text] [Related]
16. Subcutaneous administration of human C1 inhibitor with recombinant human hyaluronidase in patients with hereditary angioedema.
Riedl MA; Lumry WR; Li HH; Banerji A; Bernstein JA; Ba M; Bjrkander J; Magerl M; Maurer M; Rockich K; Chen H; Schranz J
Allergy Asthma Proc; 2016 Nov; 37(6):489-500. PubMed ID: 27931305
[TBL] [Abstract][Full Text] [Related]
17. An evidence based therapeutic approach to hereditary and acquired angioedema.
Bork K
Curr Opin Allergy Clin Immunol; 2014 Aug; 14(4):354-62. PubMed ID: 24983294
[TBL] [Abstract][Full Text] [Related]
18. Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema.
Bork K
Immunotherapy; 2014; 6(5):533-51. PubMed ID: 24635050
[TBL] [Abstract][Full Text] [Related]
19. Recombinant human C1 esterase inhibitor for the treatment of hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE).
Sabharwal G; Craig T
Expert Rev Clin Immunol; 2015 Mar; 11(3):319-27. PubMed ID: 25669442
[TBL] [Abstract][Full Text] [Related]
20. Recombinant C1-inhibitor: effects on coagulation and fibrinolysis in patients with hereditary angioedema.
Relan A; Bakhtiari K; van Amersfoort ES; Meijers JC; Hack CE
BioDrugs; 2012 Feb; 26(1):43-52. PubMed ID: 22171564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
